Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Freiburg Study of Methotrexate-based Chemo-immunotherapy and Maintenance in Elderly Primary CNS Lymphoma
2008-007645-31Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by University Hospital Freiburg. Primary endpoint: Complete response rate at 4 weeks after therapy completion. Started Mar 2009; status: completed.
02
Drugs
methotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2008-007645-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007645-31.